Viatris Company Profile

Empowering people worldwide to live

healthier at every stage of life






Dear Doctor


I am very pleased to share with you the launch of VIATRIS , a new global healthcare company
TM
formed today through the combination of Mylan and Upjohn, a legacy division of Pfizer.

At Viatris, we see healthcare not as it is, but as it should be. We act courageously and are
uniquely positioned to be a source of stability in a world of evolving healthcare needs. Our
mission is to empower people worldwide to live healthier at every stage of life. We do so via:







Access
Providing high quality, trusted medicines to patients
regardless of geography or circumstance








Leadership
Advancing sustainable operations and innovative
solutions to improve patient health








Partnership
Leveraging our collective expertise to connect
people to products and services








Our global workforce of approximately 45,000, including 14,000 commercial
employees servicing your business, works as one team to expand access to
medicines in more than 165 countries and territories. Our broad and growing
global portfolio comprises more than 1,400 molecules across a broad range of
major therapeutic areas, including best-in-class, iconic brand-name products, as
well as global key brands, generics, including branded and complex generics,
biosimilars and over-the-counter offerings. From cardiovascular health to
oncology, we offer quality treatment options across more than 10 major
therapeutic areas covering a wide variety of noncommunicable and infectious
diseases.

Our diverse and differentiated portfolio, supported by world-class commercial
and operational expertise, delivers trusted, quality medicines that treat nine out
of 10 of the World Health Organization’s (WHO) leading causes of death, and
more than 200 of our medicines are on the WHO Essential Medicines List.

We have one of the strongest global commercial infrastructures in the industry,
with a team of sales and marketing professionals providing unparalleled reach
across North America, Europe, the Asia Pacific region and emerging markets. Our
four business segments – Developed Markets, Growth Markets, Greater China,
and Japan, Australia and New Zealand (JANZ) – serve patients through more than
60,000 customers, including retail and pharmacy establishments, wholesalers,
governments, institutions, physicians and other customers.

We are headquartered in the U.S., with global centers in Pittsburgh, U.S.;
Hyderabad, India; and Shanghai, China. We have approximately 50 manufacturing
facilities around the world and our strong technical resources are comprised of
more than 2,500 scientists, more than 1,000 regulatory experts, and more than
600 medical and product safety professionals worldwide.

We strive to be a Partner of Choice™, leveraging our global reach, our partnerships,
and our regulatory, manufacturing and scientific expertise to serve as a Global
Healthcare Gateway that will enable more medicines from across the industry
TM
to reach patients like never before.

Our seasoned executive management team and board of directors bring decades
of expertise, knowledge and strategic vision to Viatris. Acting in a responsible
manner is fundamental to the Viatris mission. Wherever Viatris operates, we work
to advance responsible and sustainable operations, recognizing that all of our
actions affect our stakeholders and the communities we serve.











Please be assured that as we continue to integrate our two companies, you
should expect that it will be business as usual. Your business is extremely
important to us, and meeting your needs is our top priority. In the immediate future,
please continue to meet with your existing account representative from Mylan or
Upjohn.

Please do not hesitate to reach out if you have any questions by contacting me. To learn
more about our new company, please read our press release introducing Viatris, the
attached fact sheet and visit Viatris.com. You can also stay connected with us on Twitter
(@ViatrisInc), LinkedIn and YouTube.

While this week marks our first as Viatris, rebranding into a new company takes time,
which means you may continue to see our former company names on our products and
other materials for some time. We are committed to making the creation of Viatris and
the integration of our companies seamless for you and ensuring that our operations
and support continue uninterrupted. Should there be any changes, we will inform you
as quickly as possible.

We look forward to continuing our valuable partnership with you working toward our
common goal of empowering people worldwide to live healthier.


Sincerely,



Ester C. Tacanay
Country Manager
Mylan Philippines Inc. | PF OFG Philippines Inc.
(Viatris companies)

Please visit Viatris.com to read our Viatris Privacy Notice.

VIATRIS™ is a new kind of healthcare company, committed to providing access to medicines, advancing sustainable operations,
developing innovative solutions and leveraging our collective expertise to improve patient outcomes. Formed in 2020 through the


proven regulatory, medical and commercial capabilities to deliver quality medicines to patients when and where they need them.



OUR MISSION FAST FACTS 1
At Viatris, we see healthcare not as it is, but as it should be. We act courageously NASDAQ Ticker: VTRS
and are uniquely positioned to be a source of stability in a world of evolving
healthcare needs.
Viatris empowers people worldwide to live healthier at every stage of life. Headquartered in the U.S. with global centers
in Pittsburgh, Hyderabad and Shanghai
We do so via:
Global Workforce: ~45,000
ACCESS LEADERSHIP PARTNERSHIP
providing high quality, advancing sustainable leveraging our collective manufacturing, regulatory, commercial and
trusted medicines to operations and expertise to connect medical
patients regardless of innovative solutions to people to products
geography or circumstance improve patient health and services
Manufacturing Facilities: ~50
Across oral solid doses, injectables,
complex dosage forms and API

OUR LEADERS Annual Production Capacity:
Our seasoned executive management team and board of directors bring 80+ billion doses
decades of expertise, knowledge and strategic vision to Viatris. Together with
our dedicated and talented global workforce, our leadership is committed to Molecules: 1,400+
increasing access to medicine for patients around the world while unlocking • Portfolio that treats nine out of
value for shareholders. 10 WHO leading causes of death
• 200+ medicines on WHO Essential Medicines List

Commercial Reach:
165+ countries and territories

Customers: 60,000+
Including retail and pharmacy establishments,
wholesalers, governments, institutions and
Robert J. Coury Michael Goettler Rajiv Malik Sanjeev Narula physicians
Executive Chairman President




OU R PRODUC TS Brands Biosimilars Over-the-counter (OTC)
Our global portfolio includes Best-in-class, iconic brand- One of the industry’s Variety of OTCs, including
medicines across a broad name products and global largest and most diverse dietary supplements,
range of major therapeutic key brands global biosimilars homeopathics and cosmetics
franchises focused
areas, spanning both Generics on the areas of Active Pharmaceutical
noncommunicable and A diverse range of generic oncology, immunology, Ingredients (API)
infectious diseases. medicines, including branded endocrinology, One of the world’s largest
and complex generics ophthalmology and producers of APIs
dermatology

1 Data as of November 2020.
©2020 Viatris Inc. All Rights Reserved. VIATRIS, the VIATRIS Logo, GLOBAL HEALTHCARE GATEWAY and PARTNER OF CHOICE are trademarks of Mylan Inc., a Viatris Company.

Creating better value




for all stakeholders while addressing

unmet needs.







Our Global Healthcare Gateway
Broad Global Commercial
Reach Across Channels Patient Access
& Therapeutic Areas
Global Supply
& Manufacturing Resilient Supply Chain
Network

Expansive Technical, Innovative Health
Science & Regulatory, Legal Solutions
& Compliance Expertise


Operating Platform Sustainable Access

Disciplined
Capital Investment Future of Care
Governance As the world’s healthcare needs evolve, our unique

Fueling future more markets and patients worldwide through our unmatched global Broadening access
growth and total to medicine and
.
shareholder return infrastructure and expertise, making Viatris a true Partner of Choice™ maintaining corporate
social responsibility
Committed to Corporate Social Responsibility



PATIENT HEALTH
An industry leader with products that are capable of addressing nine of the top 10 causes of death
globally and serving more than 165 countries and territories including close to 90% of low and
lower-middle-income countries 2

EMPLOYEE HEALTH
Committed to providing a safe, positive, and productive work environment that fosters inclusion,
integrity, dignity and mutual respect


COMMUNITY HEALTH

where Viatris operates


ENVIRONMENTAL HEALTH
Responsible environmental stewardship and promoting safe and sustainable operations is a priority


GLOBAL PUBLIC HEALTH
Leverage our global footprint to advocate for responsible public policy, prioritizing patient health,
access to medicine, including in low-income countries, and the acceptance of generics and biosimilars




STAY CONNEC TED
Media Relations Investor Relations
+1.724.514.1968 +1.724.514.1813 Viatris.com Follow Viatris Follow us Subscribe to our
[email protected] [email protected] on LinkedIn @viatrisinc YouTube channel


2 According to the World Health Organization. For additional information, please visit: https://extranet.who.int/prequal/